Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Terreic acid is a naturally occurring metabolite produced by the fungus Aspergillus terreus. It is a quinone epoxide with notable antibiotic properties and functions as a covalent inhibitor of the bacterial cell wall biosynthetic enzyme UDP-N-acetylglucosamine 1-carboxyvinyltransferase (MurA), which catalyzes an essential step in peptidoglycan synthesis. Terreic acid inactivates MurA by covalently binding to Cys115 in the enzyme's active site. Additionally, it acts as an inhibitor of Bruton's tyrosine kinase (BTK), interfering with B-cell and mast cell activation by blocking BTK catalytic activity and its interaction with protein kinase C beta type (PKCβII). Terreic acid has demonstrated antibacterial and anticancer activities in vitro[1][3][4][7][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on terriec acid.